Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.35 |
| ▸ | KIF5B | P33176 | 8/20 | 0.35 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | ETV6 | P41212 | 5/20 | 0.35 |
| ▸ | CCDC6 | Q16204 | 4/20 | 0.35 |
| ▸ | LCK | P06239 | 3/20 | 0.35 |
| ▸ | CSF1R | P07333 | 3/20 | 0.35 |
| ▸ | LYN | P07948 | 3/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.35 |
| ▸ | FGR | P09769 | 3/20 | 0.35 |
| ▸ | KIT | P10721 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.35 |
| ▸ | BLK | P51451 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | NPM1 | P06748 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17836374 | 1.00 | RET (0.35) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL15031616 | 0.94 | RET (0.36) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL15007087 | 0.94 | RET (0.36) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL15007088 | 0.94 | RET (0.36) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL17836462 | 0.90 | RAB9A (0.34) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL15006923 | 0.88 | PIK3CA (0.42) | PIK3CAMTOR | |
| SCHEMBL15007092 | 0.87 | MTOR (0.36) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL15007234 | 0.87 | MTOR (0.42) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL21487 | 0.87 | MTOR (0.42) | RETKIF5BKDRETV6CCDC6 | |
| SCHEMBL20915 | 0.87 | MTOR (0.42) | RETKIF5BKDRETV6CCDC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608669-B1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2016-06-22 | — | — | EP | claimed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | claimed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | claimed |
| EP-2608669-B1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2016-06-22 | — | — | EP | disclosed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2608669-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012027236-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RPS6KA5, PAK5 | RET 498/4885KIF5B 4268/4885KDR 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.